Latest from ISC 2017
Efficacy of triple antiplatelet therapy compared with current guideline-based therapy for the prevention of recurrent stroke was evaluated in the TARDIS trial.
More patients receiving VNS experienced enhanced arm movement over a 90-day period.
Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.
Men were more likely than women to be treated with IV tPA within 30 minutes of arrival at a hospital.
As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.
The results provide good evidence for the use of contact aspiration in ischemic stroke.
Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.
The co-presentation of headache at stroke onset in children may provide clues to underlying pathophysiologic mechanisms.
Psychological distress may cause changes within cells that trigger inflammation and oxidative stress, both of which are believed to increase stroke risk.
Delays related to the determination of treatment eligibility increased door-to-needle times by more than 30 minutes compared with patients with no delays.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- Migraine and Gastrointestinal Disorders: Elucidating an Association
- Brain Health in Contact Sports: Putting It All on the Line
- Alzheimer's Disease Risk Similar in Women and Men With APOE ε3/ε4 Genotype
- Non-Invasive Magnetic Device Approved by FDA for Migraine Tx
- FDA Approves Device for Tx of Chronic Pain